諾唯贊(688105.SH):血球聯機流水線已於近期推出上市
格隆匯10月10日丨諾唯贊(688105.SH)電話會議上表示,公司全資子公司諾唯贊醫療與深圳邁瑞醫療電子股份有限公司(以下簡稱"邁瑞醫療")於 2023 年 5 月在 CACLP 展會舉行簽約儀式,就基於呼吸道病原體檢測及感染篩查的整體自動化解決方案展開合作,以實現呼吸道病原體、血常規、炎症"一管血"完成全面檢測。在雙方共同努力下,血球聯機流水線已於近期推出上市,通過邁瑞醫療 BC-7500 CS 全自動血液分析流水線與公司 QD-S2000 全自動熒光免疫分析模塊的互聯,可在血常規、CRP、SAA 檢測的基礎上,進一步全自動化、高效可靠、操作簡單地實現一管血進行 PCT、IL-6、呼吸道病原體相關項目的檢測(基於諾唯贊醫療的量子點免疫熒光技術)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.